These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 19936252)

  • 1. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
    Choi HY; Dieckmann M; Herz J; Niemeier A
    PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
    Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
    J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions.
    Katchkovsky S; Chatterjee B; Abramovitch-Dahan CV; Papo N; Levaot N
    Cell Mol Life Sci; 2022 Jan; 79(2):113. PubMed ID: 35099616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
    Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
    Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.
    Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W
    Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Bone Mass-Causing Mutant LRP5 Receptors Are Resistant to Endogenous Inhibitors In Vivo.
    Niziolek PJ; MacDonald BT; Kedlaya R; Zhang M; Bellido T; He X; Warman ML; Robling AG
    J Bone Miner Res; 2015 Oct; 30(10):1822-30. PubMed ID: 25808845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.
    Chang MK; Kramer I; Huber T; Kinzel B; Guth-Gundel S; Leupin O; Kneissel M
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5187-95. PubMed ID: 25404300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
    Lu W; Liu CC; Thottassery JV; Bu G; Li Y
    Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
    Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
    Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
    J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population.
    Mencej-Bedrac S; Prezelj J; Kocjan T; Komadina R; Marc J
    Calcif Tissue Int; 2009 Dec; 85(6):501-6. PubMed ID: 19898734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lrp4 expression by adipocytes and osteoblasts differentially impacts sclerostin's endocrine effects on body composition and glucose metabolism.
    Kim SP; Da H; Li Z; Kushwaha P; Beil C; Mei L; Xiong WC; Wolfgang MJ; Clemens TL; Riddle RC
    J Biol Chem; 2019 Apr; 294(17):6899-6911. PubMed ID: 30842262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.
    Leupin O; Piters E; Halleux C; Hu S; Kramer I; Morvan F; Bouwmeester T; Schirle M; Bueno-Lozano M; Fuentes FJ; Itin PH; Boudin E; de Freitas F; Jennes K; Brannetti B; Charara N; Ebersbach H; Geisse S; Lu CX; Bauer A; Van Hul W; Kneissel M
    J Biol Chem; 2011 Jun; 286(22):19489-500. PubMed ID: 21471202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
    Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
    Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.
    Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y
    J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
    van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
    PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wise regulates bone deposition through genetic interactions with Lrp5.
    Ellies DL; Economou A; Viviano B; Rey JP; Paine-Saunders S; Krumlauf R; Saunders S
    PLoS One; 2014; 9(5):e96257. PubMed ID: 24789067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRP4 association to bone properties and fracture and interaction with genes in the Wnt- and BMP signaling pathways.
    Kumar J; Swanberg M; McGuigan F; Callreus M; Gerdhem P; Akesson K
    Bone; 2011 Sep; 49(3):343-8. PubMed ID: 21645651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
    Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
    Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.